At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 121 enrolled
Drug / intervention
Interferon beta-1a Nebuliser solution 48 μg/mL +1 moredrug
Likely dose
Interferon beta-1a Nebuliser solution 48 μg/mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Phase IIa Study in Asthma Patients Comparing the Efficacy and Safety of Once Daily Inhaled Interferon Beta-1a to Placebo, Administered for 14 Days After the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations
In Brief
A Phase 2 clinical trial evaluating Interferon beta-1a Nebuliser solution 48 μg/mL and Placebo for Asthma. Completed, enrolled 121 participants across 35 sites in 7 countries.
Detailed Summary
A study to investigate if inhaled Interferon beta-1a is safe and tolerated, and can prevent or reduce the severity of asthma attacks when administered to asthma patients at the onset of symptoms of common cold or influenza
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Australia, Colombia, France, South Korea, Spain, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartJul 2015
Primary CompletionNov 2016
TodayJul 2026
First PostedJul 8, 2015
Enrollment StartJul 21, 2015
Primary CompletionNov 24, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.0 years ago
Interventions
Interferon beta-1a Nebuliser solution 48 μg/mLdrug
Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
Placebodrug
Placebo solution for once daily inhalation for 14 days